Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2008

Ceragenix Awarded $1.5M from Dr. Reddy’s for Progress in Commercializing EpiCeram

  • Ceragenix Pharmaceuticals  received a $1.5 million milestone payment from Dr. Reddy’s Laboratories pursuant to the firms’ agreement to jointly commercialize EpiCeram® in the U.S.

    EpiCeram® is a topical nonsteroidal skin care cream that is scheduled to be launched later this year.

    As per the agreement, Ceragenix may earn nonsales based milestone payments of up to $3.5 million upon the accomplishment of three specified events inclusive of certain product launch specific considerations. The payment received from DRL represents the accomplishment of one such event and is refundable in the event that Ceragenix cannot provide launch quantities of a properly validated and shelf-stable product. The company feels confident that it can meet those requirements.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »